Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692197 · ClinicalTrials.gov registry record · Phase 2
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01692197: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01692197 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01692197, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if E7070 in combination with idarubicin, cytarabine, and dexamethasone can help to control the disease in patients with either AML or high-risk MDS that has relapsed. The safety of the drug combination will also be studied.
Interventions
- DRUG Dexamethasone
- DRUG Cytarabine
- DRUG Idarubicin
- DRUG E7070
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2017-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01692197
The ClinicalTrials.gov registry entry for NCT01692197 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01692197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01692197 about?
NCT01692197 is a clinical study titled "E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes". The goal of this clinical research study is to learn if E7070 in combination with idarubicin, cytarabine, and dexamethasone can help to control the disease in patients with either AML or high-risk MDS that has relapsed. The safety of the drug combination will also be studied.
What is the current status of trial NCT01692197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2013-02-01. Estimated completion is 2017-06-07.
What interventions are being tested in trial NCT01692197?
The interventions under investigation include: Dexamethasone (DRUG), Cytarabine (DRUG), Idarubicin (DRUG), E7070 (DRUG).
Who is sponsoring clinical trial NCT01692197?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.